Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

Aberrant functional connectivity of resting state networks related to misperceptions and intra-individual variability in Parkinson's disease.

Miloserdov K, Schmidt-Samoa C, Williams K, Weinrich CA, Kagan I, Bürk K, Trenkwalder C, Bähr M, Wilke M.

Neuroimage Clin. 2019 Nov 5;25:102076. doi: 10.1016/j.nicl.2019.102076. [Epub ahead of print]

2.

Identification of Restless Legs Syndrome Genes by Mutational Load Analysis.

Tilch E, Schormair B, Zhao C, Salminen AV, Antic Nikolic A, Holzknecht E, Högl B, Poewe W, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Fietze I, Berger K, Lichtner P, Gieger C, Peters A, Müller-Myhsok B, Hoischen A, Winkelmann J, Oexle K.

Ann Neurol. 2019 Dec 1. doi: 10.1002/ana.25658. [Epub ahead of print]

PMID:
31788832
3.

Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease.

Maass F, Michalke B, Willkommen D, Leha A, Schulte C, Tönges L, Mollenhauer B, Trenkwalder C, Rückamp D, Börger M, Zerr I, Bähr M, Lingor P.

Neurobiol Dis. 2019 Nov 13;134:104677. doi: 10.1016/j.nbd.2019.104677. [Epub ahead of print]

4.

Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson's Disease.

Hertel J, Harms AC, Heinken A, Baldini F, Thinnes CC, Glaab E, Vasco DA, Pietzner M, Stewart ID, Wareham NJ, Langenberg C, Trenkwalder C, Krüger R, Hankemeier T, Fleming RMT, Mollenhauer B, Thiele I.

Cell Rep. 2019 Nov 12;29(7):1767-1777.e8. doi: 10.1016/j.celrep.2019.10.035.

5.

Sleep-Related Disorders in Neurology and Psychiatry.

Rémi J, Pollmächer T, Spiegelhalder K, Trenkwalder C, Young P.

Dtsch Arztebl Int. 2019 Oct 11;116(41):681-688. doi: 10.3238/arztebl.2019.0681.

6.

White matter hyperintensities are not associated with cognitive decline in early Parkinson's disease - The DeNoPa cohort.

Hanning U, Teuber A, Lang E, Trenkwalder C, Mollenhauer B, Minnerup H.

Parkinsonism Relat Disord. 2019 Dec;69:61-67. doi: 10.1016/j.parkreldis.2019.10.016. Epub 2019 Oct 19.

PMID:
31678722
7.

SEAweb: the small RNA Expression Atlas web application.

Rahman RU, Liebhoff AM, Bansal V, Fiosins M, Rajput A, Sattar A, Magruder DS, Madan S, Sun T, Gautam A, Heins S, Liwinski T, Bethune J, Trenkwalder C, Fluck J, Mollenhauer B, Bonn S.

Nucleic Acids Res. 2019 Oct 10. pii: gkz869. doi: 10.1093/nar/gkz869. [Epub ahead of print]

PMID:
31598718
8.

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group.

Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.

PMID:
31278067
9.

Pharmacological treatments of augmentation in restless legs syndrome patients.

Trenkwalder C, Paulus W.

Adv Pharmacol. 2019;84:255-265. doi: 10.1016/bs.apha.2019.02.002. Epub 2019 Mar 20.

PMID:
31229175
10.

External validation of a data-driven algorithm for muscular activity identification during sleep.

Cesari M, Christensen JAE, Sorensen HBD, Jennum P, Mollenhauer B, Muntean ML, Trenkwalder C, Sixel-Döring F.

J Sleep Res. 2019 Dec;28(6):e12868. doi: 10.1111/jsr.12868. Epub 2019 May 26.

PMID:
31131530
11.

Need for a consensus on definitions and on research methods in RBD and its prodromal phases.

Stefani A, Iranzo A, Sixel-Döring F, Videnovic A, Santamaria J, Trenkwalder C, Högl B.

Sleep. 2019 May 1;42(5). pii: zsz057. doi: 10.1093/sleep/zsz057. No abstract available.

PMID:
31091537
12.

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.

Hopfner F, Müller SH, Steppat D, Miller J, Schmidt N, Wandinger KP, Leypoldt F, Berg D, Franke A, Lieb W, Tittmann L, Balzer-Geldsetzer M, Baudrexel S, Dodel R, Hilker-Roggendorf R, Kalbe E, Kassubek J, Klockgether T, Liepelt-Scarfone I, Mollenhauer B, Neuser P, Reetz K, Riedel O, Schulte C, Schulz JB, Spottke A, Storch A, Trenkwalder C, Wittchen HU, Witt K, Wüllner U, Deuschl G, Kuhlenbäumer G.

Transl Neurodegener. 2019 Apr 3;8:11. doi: 10.1186/s40035-019-0153-0. eCollection 2019.

13.

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.

Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J.

Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1.

14.

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.

Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A.

Brain. 2019 Mar 1;142(3):744-759. doi: 10.1093/brain/awz030.

15.

Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease.

Martinez-Martin P, Rizos AM, Wetmore JB, Antonini A, Odin P, Pal S, Sophia R, Carroll C, Martino D, Falup-Pecurariu C, Kessel B, Andrews T, Paviour D, Trenkwalder C, Chaudhuri KR; EUROPAR & MDS Non‐Motor PD Study Group.

Mov Disord Clin Pract. 2018 Nov 8;6(1):57-64. doi: 10.1002/mdc3.12694. eCollection 2019 Jan.

16.

Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.

Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Erratum in: Neurology. 2019 Jun 11;92(24):1166.

17.

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.

Chahine LM, Iranzo A, Fernández-Arcos A, Simuni T, Seedorff N, Caspell-Garcia C, Amara AW, Comella C, Högl B, Hamilton J, Marek K, Mayer G, Mollenhauer B, Postuma R, Tolosa E, Trenkwalder C, Videnovic A, Oertel W; PPMI Sleep Working Group.

NPJ Parkinsons Dis. 2019 Jan 29;5:2. doi: 10.1038/s41531-018-0073-1. eCollection 2019.

18.

Reply to: A note on rotigotine for restless legs syndrome after renal transplantation.

Salminen AV, Allen RP, Högl B, Inoue Y, Oertel W, Winkelman JW, Trenkwalder C, Sampaio C, Winkelmann J.

Mov Disord. 2019 Jan;34(1):152-153. doi: 10.1002/mds.27570. No abstract available.

PMID:
30653726
19.

Reply to: Safety of dopamine agonists for treating restless legs syndrome.

Salminen AV, Allen RP, Högl B, Inoue Y, Oertel W, Winkelman JW, Trenkwalder C, Sampaio C, Winkelmann J.

Mov Disord. 2019 Jan;34(1):150-151. doi: 10.1002/mds.27571. No abstract available.

PMID:
30653723
20.

Validation of a new data-driven automated algorithm for muscular activity detection in REM sleep behavior disorder.

Cesari M, Christensen JAE, Sixel-Döring F, Trenkwalder C, Mayer G, Oertel WH, Jennum P, Sorensen HBD.

J Neurosci Methods. 2019 Jan 15;312:53-64. doi: 10.1016/j.jneumeth.2018.11.016. Epub 2018 Nov 20.

PMID:
30468824
21.

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).

Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C; DeNoPa Study Group.

Mov Disord. 2019 Jan;34(1):67-77. doi: 10.1002/mds.27492. Epub 2018 Nov 23.

PMID:
30468694
22.

Ih contributes to increased motoneuron excitability in restless legs syndrome.

Czesnik D, Howells J, Bartl M, Veiz E, Ketzler R, Kemmet O, Walters AS, Trenkwalder C, Burke D, Paulus W.

J Physiol. 2019 Jan;597(2):599-609. doi: 10.1113/JP275341. Epub 2018 Nov 24.

PMID:
30430565
23.

Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition.

Wojtala J, Heber IA, Neuser P, Heller J, Kalbe E, Rehberg SP, Storch A, Linse K, Schneider C, Gräber S, Berg D, Dams J, Balzer-Geldsetzer M, Hilker-Roggendorf R, Oberschmidt C, Baudrexel S, Witt K, Schmidt N, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Spottke A, Roeske S, Wüllner U, Wittchen HU, Riedel O, Dodel R, Schulz JB, Reetz K.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):171-179. doi: 10.1136/jnnp-2018-319008. Epub 2018 Oct 8.

PMID:
30297519
24.

Comorbidities, treatment, and pathophysiology in restless legs syndrome.

Trenkwalder C, Allen R, Högl B, Clemens S, Patton S, Schormair B, Winkelmann J.

Lancet Neurol. 2018 Nov;17(11):994-1005. doi: 10.1016/S1474-4422(18)30311-9. Epub 2018 Sep 21. Review.

PMID:
30244828
25.

Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?

Ferreira JJ, Trenkwalder C, Mestre TA.

Mov Disord. 2018 Aug;33(8):1228-1235. doi: 10.1002/mds.113. Review.

PMID:
30230626
26.

Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A.

Lancet Neurol. 2018 Sep;17(9):749-759. doi: 10.1016/S1474-4422(18)30239-4. Epub 2018 Jul 25.

PMID:
30055903
27.

Comparison of computerized methods for rapid eye movement sleep without atonia detection.

Cesari M, Christensen JAE, Kempfner L, Olesen AN, Mayer G, Kesper K, Oertel WH, Sixel-Döring F, Trenkwalder C, Sorensen HBD, Jennum P.

Sleep. 2018 Oct 1;41(10). doi: 10.1093/sleep/zsy133.

PMID:
30011023
28.

The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease.

Halsband C, Zapf A, Sixel-Döring F, Trenkwalder C, Mollenhauer B.

Mov Disord Clin Pract. 2018 Mar 1;5(2):171-176. doi: 10.1002/mdc3.12591. eCollection 2018 Mar-Apr.

29.

Polysomnographic findings in restless legs syndrome (RLS) patients with severe augmentation.

Steinke SS, Trenkwalder C, Zimmermann J, Sixel-Döring F, Muntean ML.

Sleep Med. 2018 Aug;48:79-85. doi: 10.1016/j.sleep.2018.04.010. Epub 2018 May 5.

PMID:
29860190
30.

First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire.

Martinez-Martin P, Rizos AM, Wetmore J, Antonini A, Odin P, Pal S, Sophia R, Carroll C, Martino D, Falup-Pecurariu C, Kessel B, Andrews T, Paviour D, Trenkwalder C, Chaudhuri KR; EUROPAR and MDS Non-motor PD Study Group.

Eur J Neurol. 2018 Oct;25(10):1255-1261. doi: 10.1111/ene.13691. Epub 2018 Jun 22.

PMID:
29806962
31.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

32.

Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§.

Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, Winkelman JW, Trenkwalder C, Sampaio C.

Mov Disord. 2018 Jul;33(7):1077-1091. doi: 10.1002/mds.27260. Epub 2018 May 14. Review.

PMID:
29756335
33.

Sleep-related motor and behavioral disorders: Recent advances and new entities.

Breen DP, Högl B, Fasano A, Trenkwalder C, Lang AE.

Mov Disord. 2018 Jul;33(7):1042-1055. doi: 10.1002/mds.27375. Epub 2018 May 14. Review.

PMID:
29756278
34.

[Frequent neurological diseases associated with the restless legs syndrome].

Bartl M, Winkelmann J, Högl B, Paulus W, Trenkwalder C.

Nervenarzt. 2018 Oct;89(10):1156-1164. doi: 10.1007/s00115-018-0528-y. German.

PMID:
29736677
35.

LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder.

Ouled Amar Bencheikh B, Ruskey JA, Arnulf I, Dauvilliers Y, Monaca CC, De Cock VC, Gagnon JF, Spiegelman D, Hu MTM, Högl B, Stefani A, Ferini-Strambi L, Plazzi G, Antelmi E, Young P, Heidbreder A, Mollenhauer B, Sixel-Döring F, Trenkwalder C, Oertel W, Montplaisir JY, Postuma RB, Rouleau GA, Gan-Or Z.

Parkinsonism Relat Disord. 2018 Jul;52:98-101. doi: 10.1016/j.parkreldis.2018.03.019. Epub 2018 Mar 21.

PMID:
29576439
36.

Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy.

Stefani A, Heidbreder A, Brandauer E, Guaita M, Neier LM, Mitterling T, Santamaria J, Iranzo A, Videnovic A, Trenkwalder C, Sixel-Döring F, Wenning GK, Chade A, Poewe W, Gershanik OS, Högl B.

Sleep. 2018 Jun 1;41(6). doi: 10.1093/sleep/zsy053.

37.

Pain in Parkinson's disease: facts and uncertainties.

Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O.

Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18. Review.

PMID:
29520899
38.

Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease.

Bhidayasiri R, Trenkwalder C.

Parkinsonism Relat Disord. 2018 May;50:10-18. doi: 10.1016/j.parkreldis.2018.01.008. Epub 2018 Jan 5. Review.

PMID:
29336905
39.

Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Müller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, Höglinger GU.

CNS Drugs. 2017 Dec;31(12):1093-1102. doi: 10.1007/s40263-017-0478-0.

PMID:
29139041
40.

Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.

Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B, Dauvilliers Y, Stefani A, Högl B, Poewe W, Kemlink D, Sonka K, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Teder-Laving M, Metspalu A, Hadjigeorgiou GM, Polo O, Fietze I, Ross OA, Wszolek Z, Butterworth AS, Soranzo N, Ouwehand WH, Roberts DJ, Danesh J, Allen RP, Earley CJ, Ondo WG, Xiong L, Montplaisir J, Gan-Or Z, Perola M, Vodicka P, Dina C, Franke A, Tittmann L, Stewart AFR, Shah SH, Gieger C, Peters A, Rouleau GA, Berger K, Oexle K, Di Angelantonio E, Hinds DA, Müller-Myhsok B, Winkelmann J; 23andMe Research Team; DESIR study group.

Lancet Neurol. 2017 Nov;16(11):898-907. doi: 10.1016/S1474-4422(17)30327-7. Review.

41.

Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D.

Gröschel C, Hübscher D, Nolte J, Monecke S, Sasse A, Elsner L, Paulus W, Trenkwalder C, Polić B, Mansouri A, Guan K, Dressel R.

Front Immunol. 2017 Jul 26;8:870. doi: 10.3389/fimmu.2017.00870. eCollection 2017.

42.

Diagnostic exome sequencing in early-onset Parkinson's disease confirms VPS13C as a rare cause of autosomal-recessive Parkinson's disease.

Schormair B, Kemlink D, Mollenhauer B, Fiala O, Machetanz G, Roth J, Berutti R, Strom TM, Haslinger B, Trenkwalder C, Zahorakova D, Martasek P, Ruzicka E, Winkelmann J.

Clin Genet. 2018 Mar;93(3):603-612. doi: 10.1111/cge.13124. Epub 2018 Jan 24.

PMID:
28862745
43.

The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.

Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P.

Mov Disord. 2018 Jan;33(1):88-98. doi: 10.1002/mds.27105. Epub 2017 Aug 26.

44.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.

45.

What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.

Obeso JA, Trenkwalder C.

Mov Disord. 2017 Jul;32(7):951-954. doi: 10.1002/mds.27108. No abstract available.

PMID:
28712120
46.

Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort.

Schade S, Sixel-Döring F, Ebentheuer J, Schulz X, Trenkwalder C, Mollenhauer B.

Mov Disord Clin Pract. 2017 Jun 30;4(5):755-762. doi: 10.1002/mdc3.12511. eCollection 2017 Sep-Oct.

47.

Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale.

Martinez-Martin P, Manuel Rojo-Abuin J, Rizos A, Rodriguez-Blazquez C, Trenkwalder C, Perkins L, Sauerbier A, Odin P, Antonini A, Chaudhuri KR; KPPS, EUROPAR and the IPMDS Non Motor PD Study Group.

NPJ Parkinsons Dis. 2017 Mar 15;3:8. doi: 10.1038/s41531-017-0009-1. eCollection 2017.

48.

Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.

Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A; FCM-RLS Study Investigators.

Mov Disord. 2017 Oct;32(10):1478-1482. doi: 10.1002/mds.27040. Epub 2017 Jun 23.

49.

Author response: Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Allen RP, Armstrong MJ, Trenkwalder C, Zee PC, Winkelman JW.

Neurology. 2017 Jun 13;88(24):2337-2338. doi: 10.1212/WNL.0000000000004047. No abstract available.

PMID:
28607140
50.

[Pharmacotherapy of Parkinson's disease : Aspects of drug safety].

Müller-Rebstein S, Trenkwalder C, Oertel WH, Culmsee C, Eckermann G, Höglinger GU.

Nervenarzt. 2017 Aug;88(8):888-894. doi: 10.1007/s00115-017-0345-8. Review. German.

PMID:
28497256

Supplemental Content

Loading ...
Support Center